Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors

NCT02597036 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02597036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02597036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
November 6, 2015
Completion date
May 24, 2020
Enrollment
62 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors